ARRANON

LOE Approaching

nelarabine

NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Oct 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

Nucleic Acid Synthesis Inhibitors

Pharmacologic Class:

Nucleoside Metabolic Inhibitor

Clinical Trials (5)

NCT06434467Phase 3Not Yet Recruiting

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Started May 2024
NCT01094860Phase 1Completed

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Started Jun 2010
29 enrolled
Leukemia
NCT00981799Phase 1/2Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Started Jun 2010
23 enrolled
Relapsed T-Cell Acute Lymphoblastic LeukemiaRelapsed T-Cell Lymphoblastic Lymphoma
NCT00866671N/ACompleted

Observational Study of Nelarabine in Children and Young Adults

Started Feb 2009
28 enrolled
Leukaemia, Lymphoblastic, Acute
NCT01376115N/ACompleted

Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

Started Jan 2008
343 enrolled
Cancer